viral
infecti
diseas
global
health
concern
evid
recent
outbreak
middl
east
respiratori
syndrom
ebola
viru
diseas
reemerg
zika
dengu
chikungunya
fever
viral
epidem
socioeconom
burden
caus
shortand
longterm
cost
diseas
diagnosi
treatment
well
loss
product
absente
outbreak
socioeconom
cost
underlin
necess
precis
analysi
virushost
interact
would
help
understand
diseas
mechan
develop
therapeut
intervent
combin
quantit
measur
dynam
mathemat
model
increas
understand
withinhost
infect
dynam
led
import
insight
viral
pathogenesi
transmiss
diseas
progress
furthermor
virushost
model
help
identifi
drug
target
predict
treatment
durat
achiev
cure
reduc
treatment
cost
articl
review
import
achiev
made
mathemat
model
viral
kinet
extracellular
intracellular
multiscal
level
human
immunodefici
viru
hepat
c
viru
influenza
viru
ebola
viru
dengu
viru
zika
viru
herein
focu
basic
mathemat
model
popul
scale
socal
target
celllimit
model
detail
model
regard
import
step
viral
life
cycl
combin
purpos
review
mathemat
model
viral
dynam
help
understand
virushost
interact
diseas
progress
clearanc
addit
review
differ
type
effect
therapeut
strategi
mathemat
model
use
predict
new
treatment
regimen
virus
small
oblig
intracellular
parasit
unabl
reproduc
independ
host
outbreak
infecti
viral
diseas
major
global
health
concern
circumst
evid
recent
larg
epidem
influenza
zika
fever
ebola
viru
diseas
middl
east
respiratori
syndrom
mer
accord
unit
nation
recent
zika
outbreak
caus
socioeconom
cost
approxim
us
billion
latin
america
caribbean
unit
nation
recent
studi
estim
socioeconom
cost
symptomat
dengu
case
million
us
billion
countri
shepard
et
al
number
expect
rise
come
year
factor
climat
chang
increas
air
travel
furthermor
increas
risk
global
pandem
infect
exampl
recent
global
influenza
outbreak
much
emerg
tropic
infect
dengu
viru
infect
previous
unaffect
region
unit
state
europ
mackey
et
al
control
global
threat
novel
therapeut
antivir
treatment
approach
urgent
need
amplifi
develop
novel
drug
optim
treatment
strategi
comprehens
understand
viral
infect
dynam
parasit
interact
host
well
host
defens
strategi
invad
major
import
recent
year
target
viral
agent
essenti
viral
replic
proven
highli
effect
asselah
et
al
howev
emerg
resist
direct
act
antivir
compound
lead
treatment
failur
multidrug
resist
viral
strain
poveda
et
al
order
circumv
drugresist
novel
antivir
strategi
focu
host
support
immun
respons
target
host
factor
requir
viral
life
cycl
advantag
method
higher
barrier
develop
resist
novel
opportun
broadspectrum
antivir
zeisel
et
al
mathemat
model
proven
power
tool
studi
viral
pathogenesi
yield
insight
intracellular
viral
infect
dynam
effect
immun
system
evalu
treatment
strategi
develop
drug
resist
bonhoeff
et
al
perelson
rong
perelson
perelson
ribeiro
boianelli
et
al
perelson
guedj
ciup
heffernan
model
deepen
understand
differ
scale
molecular
scale
intracellular
virushost
interact
extracellular
celltocel
infect
popul
scale
viru
spread
within
organ
whole
organ
kumberg
et
al
order
quantit
studi
viral
growth
molecular
level
investig
host
requir
limit
first
intracellular
model
develop
bacteriophag
buchholtz
schneider
eigen
et
al
endi
et
al
baculoviru
dee
shuler
semliki
forest
viru
dee
et
al
studi
celltocel
infect
earli
model
human
immunodefici
viru
hiv
ho
et
al
wei
et
al
perelson
et
al
perelson
et
al
stafford
et
al
provid
insight
pathogenesi
treatment
strategi
viru
control
immun
system
popul
scale
target
celllimit
model
nowak
bangham
bonhoeff
et
al
perelson
wodarz
nowak
extens
use
investig
virushost
interact
hiv
hepat
c
viru
hcv
influenza
viru
iav
explain
review
detail
furthermor
describ
latest
achiev
made
model
dynam
ebola
viru
ebov
dengu
viru
denv
zika
viru
zikv
caus
recent
viral
outbreak
addit
give
introduct
target
celllimit
model
extens
applic
investig
effect
direct
antivir
therapi
immun
respons
highlight
import
achiev
made
viral
model
intracellular
extracellular
integr
multiscal
level
first
mathemat
model
describ
hiv
progress
neglect
intracellular
process
take
key
player
virushost
interact
account
perelson
et
al
perelson
et
al
perelson
et
al
ho
et
al
bonhoeff
et
al
target
celllimit
model
figur
includ
three
speci
uninfect
suscept
target
cell
infect
virusproduc
cell
viru
load
v
formul
follow
system
nonlinear
ordinari
differenti
equat
ode
uninfect
target
cell
produc
constant
rate
die
rate
correspond
target
cell
halflif
ln
interact
viru
v
uninfect
target
cell
constant
infect
rate
k
target
cell
becom
infect
cell
turn
produc
infecti
viru
v
product
rate
p
due
viral
cytopath
immun
elimin
andor
apoptosi
infect
cell
die
rate
result
infect
cell
halflif
ln
viru
clear
rate
c
cell
virion
halflif
v
ln
c
per
virion
mechan
immun
elimin
nowak
bangham
bonhoeff
et
al
perelson
wodarz
nowak
averag
lifetim
uninfect
target
cell
infect
cell
viru
respect
total
number
viru
particl
n
produc
one
infect
cell
lifetim
calcul
therefor
product
rate
p
one
infect
cell
p
without
viral
infect
v
target
cell
equilibrium
nowak
may
perelson
wodarz
nowak
abil
viru
develop
infect
clear
given
basic
reproduct
ratio
r
r
repres
number
product
infect
cell
newli
gener
one
product
infect
cell
r
infect
grow
due
increas
virusproduc
infect
cell
r
refer
decreas
product
infect
cell
viral
clearanc
nowak
may
analyz
effect
antivir
drug
either
block
infect
k
andor
product
viral
particl
p
target
celllimit
model
modifi
follow
figur
k
p
neumann
k
p
describ
drug
effect
k
p
refer
case
effect
treatmenta
perfect
drug
note
treatment
k
p
simul
treatment
one
assum
system
steadi
state
treatment
initi
point
infect
andor
product
rate
modifi
depend
type
antivir
drug
use
k
andor
p
overal
drug
efficaci
tot
may
calcul
tot
k
p
critic
drug
efficaci
c
given
c
determin
transit
viral
erad
viral
persist
success
drug
therapi
would
clear
viru
tot
c
infect
becom
chronic
tot
c
dahari
et
al
relationship
certain
drug
dose
result
respons
integr
target
celllimit
model
simpl
timedepend
pharmacodynam
equat
max
describ
maximum
drug
effect
ec
drug
concentr
efficaci
c
drug
concentr
dose
appli
holford
sheiner
depend
shape
steep
underli
drug
effect
hill
coeffici
n
describ
either
sigmoid
curv
n
hyperbol
curv
otherwis
substitut
c
c
pharmacodynam
delay
drug
effect
taken
account
holford
sheiner
guedj
et
al
agebas
multiscal
model
use
order
studi
mode
action
antivir
within
virusinfect
cell
nelson
et
al
guedj
et
al
heldt
et
al
clausznitz
et
al
includ
effect
direct
act
antivir
daa
target
celllimit
model
extend
detail
intracellular
process
viral
life
cycl
figur
multiscal
model
take
age
infect
cell
account
allow
biolog
realist
represent
intracellular
process
agedepend
reaction
rate
quintela
et
al
target
celllimit
model
coupl
intracellular
process
agedepend
formul
follow
boundari
initi
condit
kvt
r
r
r
intracellular
viral
genom
r
produc
constant
rate
degrad
constant
rate
progeni
virion
assembl
secret
constant
rate
drug
effect
regard
intracellular
process
viral
genom
replic
block
viral
rna
product
virion
assemblysecret
well
increas
viral
rna
degrad
note
intracellular
viral
genom
r
infect
cell
depend
age
cell
measur
time
elaps
sinc
infect
viral
rna
level
increas
age
infect
cell
perelson
guedj
innat
adapt
immun
respons
provid
variou
mechan
fight
viral
infect
innat
immun
respons
iir
repres
first
line
defens
recogn
viru
trigger
adapt
immun
respons
air
bracial
et
al
iwasaki
medzhitov
order
studi
effect
immun
respons
viral
dynam
mathemat
model
incorpor
key
player
immun
respons
inhibit
process
viral
life
cycl
modif
target
celllimit
model
develop
take
effect
cell
iir
account
figur
done
includ
effect
interferon
ifn
model
herein
two
popul
infect
cell
describ
time
delay
infect
yet
viru
produc
cell
eclips
phase
becom
product
viru
produc
cell
averag
transit
time
f
note
die
transit
follow
time
delay
iir
ifn
f
secret
constant
rate
degrad
constant
rate
b
effect
ifn
model
decreas
transit
rate
andor
viru
product
rate
p
effect
p
baccam
et
al
moreov
effect
iir
air
coupl
target
celllimit
model
simpl
assumpt
model
iir
r
iir
repres
cytokin
recruit
cell
iir
eg
neutrophil
macrophag
air
r
air
repres
humor
immun
respons
via
bcell
antibodi
free
viru
r
iir
expand
constant
rate
die
constant
rate
b
herein
effect
iir
model
block
viru
product
rate
p
r
air
trigger
viru
recruit
constant
rate
f
clonal
expans
rate
constant
r
air
activ
neutral
viru
constant
rate
h
note
coupl
model
dead
cell
replac
new
target
cell
constant
rate
r
repres
regener
suscept
cell
handel
et
al
hiv
infect
cell
immun
system
caus
aid
within
year
post
infect
world
health
organ
estim
global
million
peopl
live
hiv
million
new
infect
million
treat
lifelong
antiretrovir
therapi
art
current
standard
care
nowaday
replic
hiv
control
suppress
combin
least
three
antiretrovir
drug
eg
revers
transcriptas
inhibitor
proteas
inhibitor
world
health
organ
drug
taken
livelong
treatment
regimen
need
adapt
regularli
keep
infect
control
date
cur
drug
vaccin
hiv
avail
major
case
infect
hiv
follow
typic
pattern
three
differ
phase
figur
simon
ho
munier
kelleh
first
week
post
infect
acut
phase
character
exponenti
increas
viral
load
accompani
rapid
deplet
cell
fauci
et
al
target
cell
hiv
soon
infect
immun
respons
kick
initi
decreas
viral
load
constant
level
socal
set
point
reach
ho
within
second
asymptomat
phase
viru
persist
year
cell
continu
slowli
declin
third
final
phase
character
gradual
deplet
cell
correl
strong
increas
viral
plasma
concentr
lead
aid
alizon
magnu
maarten
et
al
asymptomat
phase
viral
set
point
maintain
balanc
viral
clearanc
total
virion
product
rate
p
total
cv
therefor
strong
increas
viral
load
associ
lower
viral
clearanc
rate
indic
stronger
total
viral
product
rate
p
total
cv
decreas
viral
load
refer
higher
clearanc
rate
p
total
cv
perturb
system
equilibrium
eg
block
viral
product
lead
inform
rate
constant
insight
cours
viral
infect
potenti
antivir
intervent
perelson
steadi
state
absenc
art
estim
hiv
rapidli
replic
viru
produc
virion
per
day
furthermor
rapid
viru
replic
also
requir
strong
viral
clearanc
maintain
equilibrium
perelson
et
al
ramratnam
et
al
hiv
replic
cell
repres
target
infect
cell
target
celllimit
model
modifi
target
celllimit
model
ribeiro
et
al
investig
earli
plasma
viremia
post
exposur
hiv
hivposit
patient
time
delay
h
viru
becam
detect
rna
copi
per
ml
simul
shown
initi
viral
doubl
time
day
viral
load
peak
hiv
rna
copi
per
ml
day
subsequ
viral
declin
character
virion
halflif
day
c
day
moreov
earli
infect
stage
author
calcul
basic
reproduct
ratio
r
indic
rapid
viral
spread
necess
earli
intervent
order
reduc
viral
spread
prevent
develop
chronic
ribeiro
et
al
measur
viral
load
hivposit
patient
averag
first
day
primari
infect
stafford
et
al
shown
target
celllimit
model
abl
reproduc
interpati
variabl
within
highli
dynam
initi
phase
post
infect
model
simul
provid
strong
evid
initi
viral
load
declin
due
limit
target
cell
estim
lifetim
day
day
infect
virusproduc
cell
howev
target
celllimit
model
abl
mimic
data
patient
equal
well
therefor
author
suggest
process
includ
model
involv
immun
respons
cell
destruct
infect
cell
cytotox
lymphocyt
ctl
might
associ
stronger
predict
decreas
viral
load
observ
patient
stafford
et
al
year
hivposit
patient
treat
combin
antiretrovir
drug
analyz
effect
antivir
treatment
regimen
target
celllimit
model
modifi
includ
effect
revers
transcriptas
inhibitor
k
block
viral
infect
k
proteas
inhibitor
p
reduc
viral
product
p
neumann
effect
proteas
inhibitor
investig
within
first
day
oral
administr
ritonavir
perelson
et
al
follow
pharmacokinet
delay
patient
respond
well
ritonavir
treatment
continu
declin
plasma
viral
load
order
studi
viral
declin
art
perelson
et
al
modifi
target
celllimit
model
assumpt
time
drug
administr
newli
produc
virion
noninfecti
pharmacokinet
delay
day
model
reproduc
strong
declin
plasma
viremia
accord
ritonavirtr
patient
figur
model
predict
lifetim
day
virusproduc
infect
cell
day
virion
perelson
et
al
note
onset
art
system
assum
steadi
state
studi
longterm
combin
therapi
proteas
inhibitor
nelfinavir
revers
transcriptas
inhibitor
zidovudin
lamivudin
patient
respond
similar
viral
declin
pattern
figur
initi
art
biphas
viral
declin
observ
rapid
initi
reduct
viral
load
product
infect
cell
phase
follow
slower
decreas
phase
perelson
et
al
integr
longliv
cell
latent
infect
lymphocyt
becom
product
virusproduc
cell
upon
activ
second
sourc
viru
target
celllimit
model
author
identifi
longliv
infect
cell
halflif
day
compar
halflif
day
shortliv
infect
cell
continu
releas
trap
viru
main
contributor
second
phase
perelson
et
al
subsequ
studi
found
accur
estim
virion
halflif
min
hivposit
patient
plasma
apheresi
ramratnam
et
al
productivelyinfect
cell
halflif
day
combin
therapi
markowitz
et
al
continu
viral
replic
upon
activ
associ
viral
persist
repres
challeng
find
cure
hiv
even
highli
activ
antiretrovir
therapi
haart
stop
viral
product
complet
achiev
suppress
viral
load
plasma
level
detect
rna
copi
per
ml
assum
main
reason
failur
achiev
cure
viral
latenc
time
transmiss
drugresist
viru
strain
increas
result
increas
treatment
failur
rate
littl
et
al
patient
multidrug
resist
viru
raltegravir
repres
promis
new
antivir
drug
inhibit
integras
henc
prevent
strand
transfer
provir
dna
hostcel
genom
steigbigel
et
al
andrad
et
al
analyz
effect
raltegravir
monotherapi
combin
revers
transcript
inhibitor
emtricitabin
tenofovir
disoproxil
fumar
extend
target
celllimit
model
discrimin
infect
cell
without
integr
viral
dna
author
found
biphas
declin
within
first
phase
first
day
onset
art
figur
loss
infect
cell
integr
viral
dna
halflif
day
agreement
day
markowitz
et
al
identifi
main
contributor
first
subphas
phase
cell
loss
addit
integr
proviru
preintegr
infect
cell
identifi
key
contributor
slower
decay
second
subphas
phase
interestingli
halflif
unintegr
infect
cell
depend
strongli
proviru
integr
rate
estim
lie
day
andrad
et
al
cardozo
et
al
gener
model
andrad
et
al
take
longliv
infect
cell
effect
proteas
inhibitor
account
order
investig
viral
decay
presenc
absenc
raltegravir
therapi
cardozo
et
al
herein
therapi
contain
integras
strand
transfer
inhibitor
raltegravir
replac
well
first
phase
two
subphas
tradit
therapi
regimen
without
raltegravir
shown
typic
biphas
declin
viral
load
raltegravir
therapi
first
phase
associ
loss
shortliv
cell
second
phase
correspond
loss
longliv
cell
halflif
day
declin
shortliv
cell
popul
within
first
phase
separ
loss
product
virusproduc
cell
halflif
day
subphas
preintegr
cell
show
halflif
day
furthermor
longliv
cell
show
shorter
viral
integr
rate
day
compar
shortliv
cell
viral
integr
rate
day
cardozo
et
al
moreov
patient
longterm
art
palmer
et
al
studi
second
biphas
declin
within
second
phase
refer
two
sourc
viremia
persist
viru
year
figur
palmer
et
al
kim
perelson
introduc
model
extend
prolifer
latent
infect
cell
without
activ
bystand
prolifer
explain
persist
latent
reservoir
kim
perelson
chomont
et
al
observ
result
experiment
identifi
two
differ
memori
cell
contribut
longlast
reservoir
thu
persist
hiv
decad
chomont
et
al
therefor
earli
antiretrovir
intervent
necessari
limit
size
latent
reservoir
howev
understand
effect
art
within
host
cell
comprehens
investig
viral
life
cycl
necessari
reddi
yin
describ
detail
model
intracellular
viral
growth
start
revers
transcript
particl
product
matur
simul
result
sensit
analysi
predict
higher
monotherapeut
effect
revers
transcript
inhibitor
k
proteas
inhibitor
p
decreas
viral
revers
transcriptas
reduc
overal
viral
replic
moreov
found
inhibit
reva
regul
protein
virion
productionincreas
viral
product
wherea
inhibit
decreas
product
virion
reddi
yin
result
indic
incomplet
inhibit
might
compens
might
lead
advers
unwant
effect
rna
virus
hiv
genom
highli
variabl
pose
challeng
treatment
exampl
transactiv
regulatori
protein
tat
control
gene
express
activ
viral
transcript
bind
transactiv
respons
element
tar
karn
stoltzfu
shown
point
mutat
tat
may
lead
virul
hiv
strain
higher
stabil
transcript
effici
aggrav
develop
novel
antiretrovir
drug
ronsard
et
al
ronsard
et
al
ronsard
hand
tat
might
promis
vaccin
candid
shown
potenti
reduct
hiv
plasma
viremia
associ
reduc
immun
activ
gray
et
al
take
genom
variabl
genet
drift
hiv
treatment
account
import
issu
sever
author
model
withinhost
evolut
hiv
select
pressur
see
exampl
ribeiro
bonhoeff
wodarz
lloyd
ball
et
al
rong
et
al
b
xiao
et
al
interestingli
within
hiv
cohort
studi
visconti
goujard
et
al
et
al
spartac
salgado
et
al
patient
identifi
abl
control
hiv
infect
rna
copi
per
ml
art
cessat
socal
posttreat
control
moreov
hiv
infect
patient
elit
control
abl
control
suppress
plasma
viral
load
rna
copi
per
ml
natur
without
art
hiv
longterm
nonprogressor
significantli
stronger
complex
cell
respons
associ
higher
hiv
direct
prolifer
effect
kill
infect
cell
observ
oconnel
et
al
recent
conway
perelson
extend
target
celllimit
model
ctl
latent
infect
cell
herein
strong
immun
respons
dynam
elit
control
observ
respect
size
latent
reservoir
insuffici
ctl
respons
result
either
viral
rebound
posttreat
control
therefor
posttreat
control
art
cessat
depend
strongli
small
latent
reservoir
author
suggest
therapeut
vaccin
increas
strength
ctl
kill
rate
latent
revers
agent
decreas
size
latent
reservoir
conway
perelson
promis
advanc
treatment
latent
hiv
made
induct
clear
strategi
latent
reservoir
socal
kick
kill
kick
refer
activ
hiv
proviru
replic
latent
reservoir
kill
refer
clearanc
reactiv
cell
immun
system
andor
art
barton
et
al
exampl
vaccin
hivposit
patient
haart
shown
transient
increas
cell
kill
thu
temporari
decreas
latent
reservoir
persaud
et
al
anoth
possibl
activ
hiv
latent
cell
may
achiev
vorinostat
histon
deacetylas
inhibitor
vorinostat
shown
effect
induct
hiv
transcript
rest
memori
cell
patient
art
archin
et
al
understand
effect
vorinostat
rest
cell
whole
latent
reservoir
ke
et
al
develop
mathemat
model
latenc
vorinostat
therapi
could
show
vorinostat
transient
activ
hiv
transcript
reduc
reservoir
indic
necess
combin
therapi
ke
et
al
hivaid
disappear
list
top
caus
death
indic
substanti
progress
made
extens
investig
hiv
experiment
theoret
moreov
number
peopl
receiv
art
increas
million
project
million
peopl
art
boerma
et
al
bloodborn
hcv
plusstrand
rna
viru
caus
acut
hepat
c
infect
well
lifethreaten
chronic
hepat
crelat
diseas
like
liver
cirrhosi
hepatocellular
carcinoma
worldwid
million
peopl
live
chronic
hepat
c
annual
death
decad
therapi
choic
base
standard
pegyl
interferon
ifnpegifn
achiev
sustain
virolog
respons
svr
ifn
pegifn
depend
hcv
genotyp
diseas
progress
recent
daa
introduc
hcv
treatment
increas
cure
rate
world
health
organ
acut
hcv
infect
viral
load
increas
biphas
manner
reach
peak
iu
per
ml
clear
host
immun
respons
howev
hcv
patient
develop
chronic
hepat
c
persist
viru
hoofnagl
thimm
et
al
found
outcom
acut
infect
correl
hcv
control
associ
sustain
cell
respons
thimm
et
al
biphas
increas
plasma
viral
load
character
rapid
viral
rise
follow
slower
increas
viral
doubl
time
two
phase
day
respect
major
et
al
two
phase
dahari
et
al
observ
transient
reduct
viremia
introduc
gener
model
allow
inhibit
viru
product
model
simul
suggest
transient
decreas
plasma
viral
load
endogen
type
ifn
respons
block
virion
product
without
control
hcv
replic
complet
dahari
et
al
estim
absolut
efficaci
ifn
therapi
neumann
integr
effect
target
celllimit
model
inhibit
viru
product
rate
p
de
novo
infect
rate
k
initi
therapi
plasma
viral
load
declin
similar
biphas
manner
observ
hiv
patient
strong
first
follow
slower
second
decreas
result
persist
hcv
follow
pharmacokinet
delay
h
biphas
viral
declin
could
reproduc
model
partial
block
viral
product
rate
p
furthermor
clearanc
free
virion
c
therapi
efficaci
led
initi
rapid
declin
loss
infect
cell
repres
second
slower
phase
due
dosedepend
viru
reduct
author
suggest
increas
ifn
dosag
treatment
better
antivir
effect
earli
infect
estim
virion
halflif
h
c
day
infect
cell
halflif
day
day
initi
therapi
estim
virion
product
clearanc
rate
virion
per
day
neumann
patient
triphas
declin
rapid
third
phase
observ
treatment
pegyl
monotherapi
combin
ribavirin
herrmann
et
al
suggest
possibl
third
phase
declin
could
result
infect
cell
loss
enhanc
immunemedi
clearanc
ribavirin
herrmann
et
al
patient
triphas
declin
second
phase
repres
day
last
shoulder
phase
hcv
slowli
decreas
remain
constant
modifi
model
concern
prolifer
uninfect
infect
cell
dahari
et
al
could
reproduc
triphas
pattern
major
hepatocyt
assum
infect
furthermor
uninfect
hepatocyt
prolifer
rate
higher
rate
infect
cell
loss
result
almost
balanc
shoulder
phase
accord
model
simul
shoulder
phase
even
biphas
viral
declin
observ
ribavirin
effect
infect
cell
loss
inhibit
viral
product
rate
p
author
suggest
rapidli
decreas
third
phase
patient
combin
therapi
pegifn
ribavirin
might
explain
mutagen
effect
dahari
et
al
combin
therapi
pegifn
ribavirin
achiev
svr
around
patient
hcv
genotyp
mann
et
al
fri
et
al
daa
new
era
began
target
hcvencod
protein
directli
involv
viral
life
cycl
figur
scheel
rice
combin
pegifn
plu
ribavirin
daa
telapreviran
hcv
serin
proteas
inhibitorincreas
svr
around
jacobson
et
al
model
antivir
effect
telaprevir
guedj
perelson
found
higher
viral
declin
second
phase
biphas
declin
telaprevir
day
compar
ifnbas
therapi
day
neumann
author
suggest
higher
infect
cell
death
well
intracellular
degrad
viral
rna
mode
action
telaprevir
guedj
perelson
promis
hcv
inhibitor
daclatasvir
kim
et
al
associ
reduct
viremia
within
first
h
thu
offer
highli
potent
drug
gao
et
al
understand
compar
mechan
action
daclatasvir
ifn
guedj
et
al
introduc
agebas
multiscal
model
integr
intracellular
process
ie
antivir
effect
viral
rna
replic
particl
assemblysecret
target
celllimit
model
equat
figur
daclatasvir
model
predict
effect
block
viral
rna
replic
effect
inhibit
assemblysecret
viral
clearanc
rate
estim
c
day
correspond
hcv
halflif
min
intracellular
viral
rna
halflif
averag
h
compar
daclatasvir
ifn
show
dosedepend
efficaci
block
intracellular
viral
replic
block
assemblysecret
confirm
ifnmedi
viral
replic
inhibit
main
mode
action
interestingli
strong
antivir
effect
daclatasvir
observ
effici
block
intracellular
viral
replic
assemblysecret
daclatasvir
assum
inhibit
intracellular
viral
replic
kinet
compar
ifn
monotherapi
similar
agebas
multiscal
model
includ
intracellular
viral
rna
replic
viral
rna
degrad
assemblysecret
rong
et
al
investig
antivir
effect
hcv
proteas
inhibitor
danoprevir
found
danoprevir
effici
inhibit
viral
rna
replic
enhanc
viral
rna
degrad
inhibit
assemblysecret
howev
danoprevir
monotherapi
viral
clearanc
rate
estim
c
day
correspond
virion
halfliv
h
agebas
multiscal
model
strategi
shown
huge
potenti
compar
treatment
regimen
identifi
mode
action
new
daa
regard
sever
side
effect
report
ifnbas
therapi
heim
improv
therapeut
respons
daa
ifnfre
therapi
becam
desir
patient
treat
daa
mericitabin
nucleosid
hcv
polymeras
inhibitor
shown
slower
initi
viral
declin
phase
compar
eg
ifnbas
therapi
nonnucleosid
inhibitor
howev
patient
slow
monophas
viral
declin
observ
within
day
mericitabin
treatment
model
predict
shown
mericitabin
block
effect
viral
product
wherea
efficaci
increas
accumul
intracellular
phosphat
guedj
et
al
howev
faster
initi
declin
compar
mericitabin
slower
daa
found
evalu
efficaci
singl
cotreat
nucleosid
hcv
polymeras
inhibitor
sofosbuvir
compar
mono
combin
therapi
daa
famili
shown
drug
alon
highli
effect
minor
effect
combin
suggest
antivir
combin
therapi
daa
differ
famili
guedj
et
al
clinic
trial
investig
combin
sofosbuvir
ledipasvir
hcv
inhibitor
without
ribavirin
proven
highli
effect
safe
svr
afdhal
et
al
b
kowdley
et
al
use
mathemat
model
dahari
et
al
analyz
cure
time
sofosbuvir
combin
either
daclatasvir
simeprevir
ledipasvir
within
treatment
durat
patient
chronic
hepat
c
simul
show
patient
achiev
svr
less
one
remain
hepat
c
virion
interestingli
week
treatment
patient
shown
viral
load
iu
per
ml
detect
virion
patient
addit
model
predict
therapi
could
shorten
patient
result
reduc
medic
cost
dahari
et
al
limit
daabas
therapi
possibl
develop
viral
resist
ie
emerg
drugescap
variant
depend
patient
group
hcv
genotyp
treatment
regimen
pawlotski
patient
treat
telaprevir
period
kieffer
et
al
found
increas
plasma
viral
load
also
increas
drugresist
variant
replac
wildtyp
hcv
almost
complet
day
kieffer
et
al
therefor
attent
must
paid
find
effect
therapi
regimen
develop
drug
resist
avoid
anoth
altern
treatment
strategi
directli
target
viru
rather
aim
cellular
cofactor
sinc
viru
depend
strongli
live
host
cell
effici
replic
exampl
cyclophilin
b
identifi
cellular
factor
modul
rna
bind
activ
hcv
polymeras
thu
regul
hcv
replic
watashi
et
al
liu
et
al
report
interact
cyclophilin
hcv
polymeras
predict
cyclophilin
major
key
host
factor
activ
replicas
liu
et
al
cyclophilin
inhibitor
alisporivir
gallay
lin
hopkin
et
al
nim
lawitz
et
al
confirm
potenti
disrupt
hcv
replic
find
host
factor
proven
import
detail
understand
hcv
life
cycl
host
interact
character
intracellular
viral
replic
detail
dahari
et
al
develop
detail
mathemat
model
investig
singl
step
intracellular
rna
replic
model
cytoplasm
translat
rna
replic
within
replic
compart
shown
hcv
regul
plusstrand
minusstrand
relat
strandspecif
affin
hcv
polymeras
addit
author
shown
viru
benefit
encapsul
genom
replic
insid
membran
replic
site
dahari
et
al
use
extend
model
base
detail
measur
initi
replic
kinet
binder
et
al
mimick
highli
dynam
initi
phase
within
first
hour
post
infect
steadi
state
minusstrand
rna
plusstrand
rna
protein
activ
import
find
model
role
protect
replic
compart
hcv
replic
genom
one
hand
compart
appear
protect
viru
antivir
mechan
requir
establish
success
replic
hand
compart
also
seem
limit
viral
growth
thu
exert
tight
control
viral
dynam
integr
host
factor
model
author
show
cellular
cofactor
involv
format
membran
replic
site
initi
minusstrand
synthesi
respons
differ
replic
efficaci
differ
cell
line
binder
et
al
recent
benzin
et
al
estim
halfliv
replicas
complex
complex
viral
cellular
protein
associ
viral
genom
synthesi
slowli
rapidli
replic
hcv
strain
mathemat
model
distinguish
differ
viral
plusstrand
rna
genomesrna
associ
translat
rna
respons
rna
synthesi
membran
web
replicas
complex
well
rna
assembl
pack
virion
author
estim
replicas
complex
halfliv
h
fast
replic
strain
h
slow
replic
strain
specul
differ
aminoacid
nonstructur
ns
protein
respons
replicas
complex
format
well
interact
host
protein
underli
observ
differ
halfliv
furthermor
antivir
efficaci
integr
effect
inhibitor
elbasvir
inhibitor
sofosbuvir
compound
sofosbuvir
inhibit
plusand
minusstrand
synthesi
elbasvir
block
format
new
replicas
complex
viral
assembl
compound
inhibit
format
replicas
complex
slowli
replic
strain
model
predict
block
viral
assembl
rna
increasingli
use
translat
redirect
low
fast
replic
viral
strain
benzin
et
al
clausznitz
et
al
develop
multiscal
model
combin
target
celllimit
model
detail
intracellular
replic
investig
specif
effect
daclatasvir
target
hcv
within
first
day
post
drug
administr
daclatasvir
exact
mode
action
still
unknown
author
compar
differ
put
mechan
concern
initi
longterm
dynam
block
viral
replic
affect
longterm
dynam
block
viral
assemblysecret
effect
initi
longterm
dynam
interestingli
complet
inhibit
viral
assemblysecret
erad
viru
addit
shown
host
factor
affect
longterm
dynam
repres
main
paramet
individu
differ
viral
replic
efficaci
clausznitz
et
al
mous
model
mailli
et
al
shown
inhibit
viral
entri
monoclon
antibodi
shown
highli
effect
prevent
hcv
infect
without
emerg
resist
use
target
celllimit
model
extend
effect
monoclon
antibodi
inhibit
de
novo
infect
rate
k
model
predict
clearanc
infect
cell
prevent
new
infect
mailli
et
al
thu
inhibit
cellular
cofactor
mediat
viral
entri
might
promis
strategi
prevent
erad
hcv
season
influenza
acut
infect
respiratori
tract
caus
influenza
viru
type
b
c
annual
averag
million
peopl
worldwid
infect
diseas
often
associ
sever
symptom
lead
death
per
year
two
class
antivir
drug
avail
influenza
neuraminidas
inhibitor
proton
channel
blocker
howev
effect
strategi
season
influenza
infect
prevent
vaccin
proven
safe
effect
year
world
health
organ
cours
infect
iav
character
exponenti
growth
viral
load
reach
maximum
day
post
infect
figur
within
follow
day
viral
load
declin
viru
becom
undetect
within
day
post
infect
wright
et
al
baccam
et
al
modifi
target
celllimit
model
take
rapid
dynam
iav
account
model
neglect
regener
death
target
cell
baccam
et
al
assumpt
progeni
viru
undetect
within
first
h
sedmak
grossberg
eclips
phase
incorpor
model
character
time
delay
cell
infect
viru
product
order
model
eclips
phase
author
introduc
two
differ
infect
cell
popul
yet
viru
produc
infect
cell
eclips
phase
activ
viru
produc
infect
cell
equat
data
patient
experiment
infect
iav
mathemat
model
without
eclips
phase
analyz
author
could
show
model
fit
patient
data
equal
well
wherea
eclips
phase
model
estim
biolog
reason
paramet
halflif
free
virion
h
furthermor
h
delay
figur
cours
iav
infect
viral
load
innat
immun
respons
interferon
adapt
immun
respons
antibodi
ctl
inspir
handel
wright
et
al
infect
cell
produc
viru
h
lead
averag
lifetim
h
infect
cell
addit
author
calcul
basic
reproduct
ratio
r
indic
rapid
viral
spread
r
cell
infect
epitheli
cell
upper
respiratori
tract
suggest
earli
initi
treatment
crucial
interestingli
patient
second
peak
viral
load
observ
extend
target
celllimit
model
effect
ifn
equat
second
peak
might
explain
decreas
antivir
effect
ifn
baccam
et
al
iav
infect
ifn
detect
h
post
infect
reach
maximum
h
robert
et
al
ifn
play
major
role
inhibit
viral
infect
establish
antivir
state
samuel
turn
iav
protein
identifi
ifn
antagonist
circumv
ifnmedi
antivir
respons
correl
pathogen
garciasastr
et
al
saenz
et
al
extend
target
celllimit
model
regul
iir
herein
ifn
releas
infect
cell
induc
antivir
state
turn
target
cell
refractori
cell
model
predict
demonstr
major
role
ifn
control
earli
infect
protect
target
cell
saenz
et
al
captur
interact
iav
iir
air
pawelek
et
al
includ
antivir
state
refractori
cell
well
ifninduc
infect
cell
kill
target
celllimit
model
author
shown
earli
viral
infect
might
control
target
cell
deplet
rapid
viral
postpeak
declin
could
explain
enhanc
infect
cell
kill
mediat
cytokin
natur
killer
cell
cell
activ
ifn
moreov
author
abl
mimic
bimod
pattern
rebound
plasma
viral
load
observ
patient
baccam
et
al
assum
second
peak
due
loss
antivir
effect
ifn
lead
recoveri
target
cell
pawelek
et
al
compar
dynam
four
differ
iav
strain
mous
model
manchanda
et
al
shown
strainspecif
rebound
viremia
lead
second
peak
furthermor
model
predict
explain
rebound
persist
inflamm
correl
diseas
sever
manchanda
et
al
air
mainli
mediat
ctl
antibodi
appear
day
primari
infect
day
reinfect
result
faster
memori
cellmedi
secondari
respons
tamura
kurata
handel
et
al
extend
target
celllimit
model
simpl
defens
mechan
immun
mediat
eg
inflammatori
cytokin
well
antibodi
ctl
equat
shown
model
either
antibodi
kill
free
virion
ctlmediat
immun
respons
kill
infect
cell
fit
data
equal
well
distinct
underli
mechan
air
possibl
avail
data
handel
et
al
miao
et
al
combin
ctl
antibodi
igg
igm
within
mathemat
model
confirm
necess
ctl
igm
infect
clearanc
lead
averag
halfliv
infect
cell
day
free
virion
min
absenc
air
day
halfliv
infect
cell
estim
day
free
virion
h
furthermor
model
predict
contribut
ctl
kill
infect
cell
mainli
igm
clear
viral
load
due
low
contribut
igg
primari
infect
clearanc
author
suggest
role
igg
togeth
cell
gener
memori
therefor
second
immun
respons
miao
et
al
recommend
prevent
influenza
infect
vaccin
reduc
sever
complic
death
especi
elderli
howev
due
lower
antibodi
respons
elderli
age
year
vaccin
efficaci
compar
young
adult
goodwin
et
al
hernandezvarga
et
al
studi
impact
age
immun
respons
cours
iav
infect
shown
limit
stimul
adapt
immun
cell
led
reduc
viral
growth
lower
r
immun
age
mice
addit
delay
day
infect
clearanc
correl
delay
increas
cell
age
mice
indic
key
role
cell
infect
clearanc
therefor
lower
viral
burden
might
trigger
immun
respons
insuffici
explain
strike
differ
infect
control
viral
titer
elderli
young
mice
hernandezvarga
et
al
howev
experiment
result
model
predict
valid
immun
age
mice
studi
efficaci
vaccin
elderli
valid
result
human
would
appropri
obvious
complic
model
effect
cell
popul
recurr
iav
infect
zarnitsyna
et
al
shown
increas
cell
level
led
decreas
viral
load
shorter
recoveri
time
model
cao
et
al
confirm
relationship
faster
recoveri
increas
level
effector
cell
thu
induct
cell
might
promis
vaccin
strategi
instead
boost
antibodi
respons
might
lead
antigen
mutat
constantli
evolv
new
influenza
strain
cao
et
al
zarnitsyna
et
al
effect
amantadin
antivir
agent
act
ion
channel
blocker
includ
eclips
model
baccam
et
al
affect
infect
rate
k
target
cell
virion
author
show
maximum
drug
efficaci
amantadin
explain
possibl
rapid
develop
drug
resist
character
viral
dynam
adamantan
treatment
eg
amantadin
therefor
import
take
emerg
drugresist
account
beauchemin
et
al
investig
effect
oseltamivir
neuraminidas
inhibitor
use
model
combin
antivir
treatment
regimen
iir
air
well
score
system
symptom
emerg
drug
resist
random
event
author
show
prophylact
use
presymptomat
phase
oseltamivir
low
dose
may
caus
higher
emerg
drug
resist
incub
period
due
insuffici
air
eg
natur
killer
cell
initi
durat
treatment
drug
dose
well
treatment
frequenc
identifi
crucial
factor
emerg
drug
resist
kamal
et
al
studi
time
cours
influenza
infect
without
oseltamivir
effect
virion
product
rate
inhibit
releas
newli
produc
virion
viral
shed
shown
sooner
initi
oseltamivir
treatment
correl
decreas
viral
secret
durat
investig
effect
combin
treatment
found
effect
oseltamivir
togeth
antivir
drug
affect
viral
clearanc
signific
better
effect
reduc
viral
load
regardless
onset
therapi
kamal
et
al
heldt
et
al
develop
agebas
multiscal
model
combin
viral
life
cycl
celltocel
transmiss
aim
investig
effect
daa
author
found
promis
antivir
strategi
interf
viral
transcript
replic
protein
synthesi
nuclear
export
assemblysecret
inhibit
earli
step
replicationviru
entrycaus
delay
viru
product
addit
show
drug
could
fact
increas
viru
product
indic
import
detail
understand
dynam
event
viru
life
cycl
heldt
et
al
schelker
et
al
investig
earli
event
viral
life
cycl
within
diffus
model
approach
identifi
time
point
endocytosi
distanc
diffus
nucleu
bottleneck
support
cytosol
degrad
limit
factor
effici
viru
replic
schelker
et
al
ebov
type
zair
caus
largest
outbreak
date
west
africa
report
diseas
case
death
untreat
acut
ebola
infect
caus
sever
ill
fatal
rate
averag
world
health
organ
ebov
negativestrand
rna
viru
replic
immun
cell
abil
persist
immuneprivileg
site
central
nervou
system
may
thu
lead
viral
relaps
jacob
et
al
specif
treatment
current
avail
recent
clinic
trial
newli
develop
vaccin
rvsvzebov
shown
highli
protect
ebola
diseas
henaorestrepo
et
al
captur
ebola
infect
dynam
nguyen
et
al
use
target
celllimit
model
compar
ebov
pandem
iav
ebov
infect
time
significantli
slower
iav
infect
time
h
vs
min
holder
et
al
pinilla
et
al
nguyen
et
al
furthermor
viral
replic
rate
estim
ffuml
day
cell
ebov
henc
highli
effici
virion
halfliv
h
c
day
unfortun
result
uncertain
due
paramet
identifi
problem
nonetheless
target
celllimit
model
confirm
viral
growth
seen
experiment
data
start
day
post
infect
complet
target
cell
deplet
day
madelain
et
al
extend
target
celllimit
model
eclips
phase
nonvirusproduc
infect
cell
found
halflif
virusproduc
infect
cell
h
basic
reproduct
ratio
r
author
furthermor
studi
antivir
effect
mice
treat
favipiravir
antivir
drug
block
rnadepend
rna
polymeras
broad
spectrum
rna
virus
furuta
et
al
inhibit
viru
product
rate
p
found
sharp
decreas
viral
load
associ
increas
drug
efficaci
day
onset
treatment
sinc
favipiravir
achiev
maxim
efficaci
day
earli
treatment
initi
suggest
madelain
et
al
patient
data
survivor
fatal
uganda
ebola
diseas
outbreak
martyushev
et
al
studi
relationship
viru
replic
diseas
sever
purpos
extend
target
celllimit
model
two
target
cell
popul
potenti
target
cell
recruit
via
proinflammatori
cytokin
eg
recruit
macrophag
hepatocyt
splenocyt
endotheliocyt
becom
suscept
target
cell
primari
target
viral
replic
eg
macrophag
dendrit
cell
ebola
diseas
sever
describ
log
higher
plasma
viral
load
correl
extens
recruit
potenti
target
cell
higher
basic
reproduct
ratio
r
fatal
case
r
nonfat
case
henc
higher
viral
load
fatal
case
massiv
infectionhypersecret
cytokin
activ
virusproduc
replic
cell
associ
potenti
sever
ebola
diseas
wauquier
et
al
martyushev
et
al
addit
antivir
intervent
antibodybas
therapi
affect
de
novo
infect
k
ii
sirnabas
treatment
block
viral
product
p
iii
nucleosid
analogbas
therapi
eg
favipiravir
evalu
monoand
combin
therapi
combin
nucleosid
analogbas
therapi
sirnabas
turn
effici
initi
day
post
symptom
onset
antibodybas
therapi
seem
insuffici
martyushev
et
al
author
demonstr
critic
inhibit
rate
fatal
case
nonfat
case
need
prevent
fatal
outcom
ebola
viru
diseas
denv
positivestrand
rna
viru
infect
annual
million
peopl
worldwid
denv
spread
mainli
mosquito
aed
aegypti
aed
albopictu
also
transmit
chikungunya
viru
yellow
fever
viru
zikv
four
serotyp
denv
caus
flulik
ill
occasion
associ
sever
complic
like
hemorrhag
fever
clear
dengu
infect
provid
serotypespecif
lifelong
immun
secondari
infect
anoth
serotyp
result
sever
dengu
diseas
current
antivir
treatment
avail
recent
develop
dengu
vaccin
cydtdv
villar
et
al
suggest
endem
region
world
health
organ
explain
interindividu
differ
denv
infect
dynam
clapham
et
al
extend
target
celllimit
model
simpl
air
moreov
differ
primari
secondari
infect
could
explain
variat
immun
respons
secondari
infect
immun
responserel
paramet
shown
higher
valu
eg
immun
cell
prolifer
rate
viru
clearanc
rate
interestingli
infect
rate
constant
k
also
reach
higher
valu
secondari
infect
compar
primari
infect
support
hypothesi
antibodydepend
enhanc
antibodi
mediat
viru
entri
thu
increas
viral
infect
secondari
infect
clapham
et
al
subsequ
studi
clapham
et
al
investig
antibodi
dynam
within
target
celllimit
model
predict
role
igm
igg
cours
dengu
infect
show
primari
infect
mainli
clear
igm
secondari
infect
clear
igg
igm
result
refer
key
role
igm
denv
infect
clearanc
furthermor
best
fit
result
found
assum
antibodi
directli
neutral
free
viru
compar
clearanc
infect
cell
eg
via
antibodydepend
cell
cytotox
howev
model
predict
shown
short
lifespan
infect
cell
day
refer
addit
immunemedi
clearanc
mechan
clapham
et
al
benshachar
koell
develop
seri
withinhost
dengu
model
integr
key
player
iir
air
order
investig
viral
dynam
develop
sever
dengu
diseas
extend
target
celllimit
model
iir
abl
reproduc
viral
dynam
primari
infect
furthermor
show
higher
rate
constant
infect
k
evid
antibodydepend
enhanc
infect
cell
death
evid
cell
respons
increas
sever
necessari
mimic
viral
dynam
secondari
infect
benshachar
koell
recent
benshachar
et
al
refin
result
investig
serotypespecif
differ
higher
infect
rate
constant
k
estim
compar
model
consist
vari
replic
efficaci
differ
dengu
serotyp
benshachar
et
al
populationbas
delay
model
coupl
iir
schmid
et
al
studi
attenu
viral
spread
denv
mutant
propos
vaccin
candid
work
show
denv
mutant
faster
ifn
activ
product
establish
antivir
state
infect
cell
lead
decreas
viral
product
spread
compar
wildtyp
denv
furthermor
model
show
stronger
impact
autocrin
ifn
comparison
paracrin
effect
reduc
viral
spread
schmid
et
al
zikv
plusstrand
rna
viru
mainli
carri
transmit
aed
mosquito
sexual
transmiss
well
report
foy
et
al
musso
et
al
dortenzio
et
al
human
infect
zikv
usual
caus
mild
diseas
similar
symptom
seen
denv
infect
howev
recent
outbreak
brazil
estim
zika
case
heukelbach
et
al
zikv
associ
neurolog
complic
syndrom
fetal
microcephali
world
health
organ
recent
best
et
al
develop
seri
model
without
incorpor
immun
respons
fit
plasma
viral
load
data
zikvinfect
nonhuman
primat
within
model
seri
target
celllimit
model
extend
eclips
phase
distinguish
nonact
activ
virusproduc
infect
cell
bestsuit
model
reproduc
data
furthermor
incorpor
key
player
iir
air
eg
ifn
natur
killer
cell
respect
improv
model
fit
thu
neglect
simpl
eclips
phase
model
estim
eclips
phase
h
alreadi
observ
via
model
osuna
et
al
basic
reproduct
ratio
r
degrad
rate
product
infect
cell
estim
day
correspond
lifetim
h
author
furthermor
includ
effect
antivir
therapi
inhibit
viral
product
rate
broad
spectrum
rna
polymeras
inhibitor
favipiravir
time
undetect
plasma
viremia
could
reduc
day
initi
therapi
start
time
point
infect
day
post
infect
therapi
initi
day
post
infect
led
result
compar
drug
treatment
lead
undetect
plasma
viral
load
day
post
infect
best
et
al
integr
immun
respons
via
ifn
neutral
antibodi
eclips
phase
model
aid
et
al
found
posit
effect
control
viral
infect
peripheri
overal
best
fit
achiev
initi
ifn
respons
day
activ
neutral
antibodi
start
day
aid
et
al
year
populationbas
target
celllimit
model
use
describ
dynam
varieti
virus
interdisciplinari
research
combin
experiment
measur
mathemat
model
improv
understand
virushost
interact
help
quantifi
key
paramet
viral
life
cycl
simpl
mathemat
model
allow
investig
circumst
lead
viral
erad
develop
chronic
infect
equilibrium
viru
product
immunemedi
clearanc
studi
antivir
drug
treatment
target
celllimit
model
enabl
identif
drug
efficaci
mode
action
moreov
simpl
extens
model
led
insight
differ
pattern
viral
declin
drug
treatment
evalu
differ
treatment
regimen
take
immun
system
account
mathemat
model
help
identifi
key
player
viral
clearanc
comprehens
quantit
dynam
understand
virushost
interact
vital
advanc
antivir
therapi
achiev
model
entir
viral
life
cycl
viru
entri
particl
product
would
support
predict
precis
mode
action
daa
would
also
help
identifi
evalu
new
treatment
opportun
potenti
broadspectrum
antivir
drug
drug
interact
directli
viral
protein
shown
enorm
potenti
may
lead
emerg
viru
strain
mutat
multidrug
resist
treatment
failur
therefor
futur
research
might
focu
resist
free
antivir
drug
eg
target
host
factor
prevent
viral
diseas
vaccin
support
knowledgebas
design
drug
vaccin
comprehens
view
immun
respons
viral
infect
necessari
regard
complex
interplay
first
line
defens
iir
establish
immun
respons
memori
air
question
aris
viru
hide
circumv
immun
respons
patient
abl
clear
infect
would
develop
chronic
infect
major
patient
furthermor
model
techniqu
may
consid
timedepend
dynam
focu
well
spatial
scale
combin
time
space
scale
agentbas
model
may
help
character
viral
spread
tissu
within
organ
whole
human
bodi
addit
complex
interplay
viru
immun
system
may
studi
agentbas
model
rel
simpl
rule
bauer
et
al
graw
perelson
kumberg
et
al
mathemat
model
address
import
question
concern
virushost
interact
may
contribut
answer
open
question
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
lk
receiv
fund
bmbf
erasysapp
project
sysvirdrug
